Remington-Davis Clinical Research

Fast-track research with trusted experts who value the patient experience.

Remington-Davis is an experienced, fast-paced clinical research site that conducts complex drug and device studies in multiple therapeutic areas. We focus on the collection of quality data and providing a high level of sponsor and patient satisfaction.

Experience You Can Trust

- Over 30 years of research excellence
- 600+ Industry-sponsored trials
- Phase 1-4
- Vaccines, biologics, device, biosimilars
- 141 years of investigator experience:

Principal Investigator	Board Certification	# of Studies	Experience
Dr. Edward Cordasco	Pulmonary Medicine	160	31 Years
Dr. Brian Zeno	Pulmonary Medicine	128	20 Years
Dr. Roy St. John	Pulmonary Medicine	72	26 Years
Dr. Michelle Chambers	Dermatology	45	17 Years
Dr. Krishna Rayapudi	Gastroenterology	12	9 Years
Dr. Ian Baird	Infectious Disease	262	38 Years
Dr. Kevin Schroeder	Nephrology	8	6 Years

Our State-of-the-Art Facility

Infrastructure

- 7,500-square-foot research clinic
- 8 treatment rooms
- 5 overnight rooms with shower and kitchen
- Continuous IP temperature monitoring
- 4 private monitoring spaces
- On-site record storage
- -80° C freezer
- Secure drug storage with DEA Class II license

Community Engagement Program

- Sponsor and attend local festivals and community-based events
- Host wellness clinics at Remington-Davis that include free health screenings
- Collaborate with providers and clinics to integrate trials with patient care
- Manage ongoing and new partnerships through our senior PI, Roy St. John, MD
- Connect with target populations via IRB/sponsored-approved digital ads

The result: a patient database with a nearly 37% diversity rate

Our Services

Therapeutic Areas

- Vaccine Studies
- General Medicine/Internal Medicine
- Endocrinology Studies
- Dermatology Studies
- Gastroenterology Studies
- Nephrology Studies
- Pulmonary Studies
- Phase 1

Efficiency at Every Step

- Contract turnaround = 24 hours
- Regulatory packet completion = 72 hours
- eRegulatory for instant access
- eSource for realtime monitoring
- Greenlight to first patient = 1 week
- Data entry/query resolution = 24 hours

Proof of Rapid Enrollment

- Phase 1 - 36-hour infusion, 5-day sequestration, 85 subjects in 3 months
- COVID-19 Treatment - 235 subjects in 6 months
- Diabetes Device - 360 subjects in 6 weeks
- Migraine - 60 subjects in 9 days
- Vaccine - 80 specialty subjects in 2 months

"You and your team are doing fantastic with the STRIVE study. I would clone your site if I could! Such a pleasure to work with your team."

REMINGTON-DAVIS

Remington-Davis, Inc.
1335 Dublin Road, Suite 106A
Columbus, OH 43215

(614) 487-2560

www.remdavis.com